ClinicalTrials.gg
CompletedNCT00994461Updated Feb 2, 2021Results posted

Study Of Celecoxib In Healthy Subjects

A Phase 4 interventional study of Celecoxib and Loxoprofen in Healthy Volunteers, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 3 sites in Japan. Open to participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
40 Years to 74 Years
Sex
All
01

Study summary

A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Endoscopy
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Volunteers

Exclusion criteria

Exclusion Criteria:

  • Endoscopic evidence of ulceration, erosion or active bleeding etc. in the esophagus, stomach, pylorus and/or duodenum prior to treatment endoscopy
  • A history of gastrointestinal ulcer
  • Any use of celecoxib, nonsteroidal anti-inflammatory drugs (including aspirin), anti-ulcer medication, antacids, systemic or antibiotics within four weeks prior to the first dose of study medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Celecoxib

    Drug: Celecoxib

  • Active comparator
    Loxoprofen

    Drug: Loxoprofen

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Celecoxib 100mg tablet twice a day with meal for 2 weeks

  • Loxoprofen 60mg tablet three times a day with meal for 2 weeks

  • DrugPlacebo

    Placebo tablet three times a day with meal for 2 weeks

06

What researchers measure

Primary outcomes

  1. Incidence of Gastroduodenal Ulcers

    The percentage of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.

    Time frame: 2 weeks

Secondary outcomes

  1. Incidence of Any Gastric, and Duodenal Ulcers

    The percentage of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.

    Time frame: 2 weeks

  2. Incidence of Any Gastroduodenal, Gastric, and Duodenal Ulcers and/or Erosions

    The percentage of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment (The number of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.

    Time frame: 2 weeks

  3. Post-treatment Gastroduodenal Endoscopic Scores (According to Mucosal Grading Scale)

    Number of subjects for each gastroduodenal endoscopic score (according to Mucosal Grading Scale) after 2 weeks treatment (Score 0 = normal mucosa (no visible lesions); Score 1 = 1 to 10 petechiae; Score 2 = more than 10 petechiae; Score 3 = 1 to 5 erosions; Score 4 = 6 to 10 erosions; Score 5 = 11 to 25 erosions; Score 6 = more than 25 erosions; Score 7 = ulcer)

    Time frame: 2 weeks

  4. Number of Gastroduodenal Ulcers in Each Subject

    Number of subjects for each number of gastroduodenal endoscopic ulcers after 2 weeks treatment (An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.)

    Time frame: 2 weeks

  5. Number of Gastroduodenal Erosions in Each Subject

    Number of subjects for each number of gastroduodenal endoscopic erosions after 2 weeks treatment (An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.)

    Time frame: 2 weeks

  6. Incidence of Treatment-emergent, All-causality GI Body System Adverse Events

    The percentage of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment (The number of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment divided by participants multiplied by 100.)

    Time frame: 2 weeks

07

Results

Posted May 17, 2011

Participant flow

Subjects were screened at 3 centers in Japan.

Participant flow — Overall Study
MilestoneCelecoxibLoxoprofenPlacebo
Started767637
Completed747537
Not completed210
Withdrew: Adverse event210

Outcome measures

PrimaryIncidence of Gastroduodenal Ulcers

The percentage of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.

Time frame:
2 weeks
Reported as:
Number · Percent
Incidence of Gastroduodenal Ulcers
PercentCelecoxibLoxoprofenPlacebo
Incidence of Gastroduodenal Ulcers1.427.62.7
Statistical analysis
  • Celecoxib vs Loxoprofen · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel (CMH) test stratified by H. pylori status was employed for the comparison of celecoxib and loxoprofen with placebo. The multiplicity of test was not adjusted because these comparisons were for the secondary objective.)CMH test stratified by H. pylori status was employed. Continuous correction was used.
SecondaryIncidence of Any Gastric, and Duodenal Ulcers

The percentage of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.

Time frame:
2 weeks
Reported as:
Number · Percent
Incidence of Any Gastric, and Duodenal Ulcers
PercentCelecoxibLoxoprofenPlacebo
Gastric ulcers025.02.7
Duodenal ulcers1.45.30
SecondaryIncidence of Any Gastroduodenal, Gastric, and Duodenal Ulcers and/or Erosions

The percentage of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment (The number of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.

Time frame:
2 weeks
Reported as:
Number · Percent
Incidence of Any Gastroduodenal, Gastric, and Duodenal Ulcers and/or Erosions
PercentCelecoxibLoxoprofenPlacebo
Gastroduodenal ulcers and/or erosions36.553.924.3
Gastric ulcers and/or erosions35.153.924.3
Duodenal ulcers and/or erosions4.15.30
SecondaryPost-treatment Gastroduodenal Endoscopic Scores (According to Mucosal Grading Scale)

Number of subjects for each gastroduodenal endoscopic score (according to Mucosal Grading Scale) after 2 weeks treatment (Score 0 = normal mucosa (no visible lesions); Score 1 = 1 to 10 petechiae; Score 2 = more than 10 petechiae; Score 3 = 1 to 5 erosions; Score 4 = 6 to 10 erosions; Score 5 = 11 to 25 erosions; Score 6 = more than 25 erosions; Score 7 = ulcer)

Time frame:
2 weeks
Reported as:
Number · Participants
Post-treatment Gastroduodenal Endoscopic Scores (According to Mucosal Grading Scale)
ParticipantsCelecoxibLoxoprofenPlacebo
Score 0383322
Score 1826
Score 2100
Score 322198
Score 4410
Score 5000
Score 6000
Score 71211
SecondaryNumber of Gastroduodenal Ulcers in Each Subject

Number of subjects for each number of gastroduodenal endoscopic ulcers after 2 weeks treatment (An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.)

Time frame:
2 weeks
Reported as:
Number · Participants
Number of Gastroduodenal Ulcers in Each Subject
ParticipantsCelecoxibLoxoprofenPlacebo
0 ulcer735536
1 ulcer1101
2 ulcers050
3 ulcers020
4 ulcers000
5 ulcers000
6 ulcers010
7 ulcers020
8 ulcers010
9 ulcers000
10 or more ulcers000
SecondaryNumber of Gastroduodenal Erosions in Each Subject

Number of subjects for each number of gastroduodenal endoscopic erosions after 2 weeks treatment (An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.)

Time frame:
2 weeks
Reported as:
Number · Participants
Number of Gastroduodenal Erosions in Each Subject
ParticipantsCelecoxibLoxoprofenPlacebo
0 erosion474129
1 erosion14135
2 erosions431
3 erosions592
4 erosions040
5 erosions030
6 erosions210
7 erosions110
8 erosions010
9 erosions000
10 or more erosions100
SecondaryIncidence of Treatment-emergent, All-causality GI Body System Adverse Events

The percentage of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment (The number of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment divided by participants multiplied by 100.)

Time frame:
2 weeks
Reported as:
Number · Percent
Incidence of Treatment-emergent, All-causality GI Body System Adverse Events
PercentCelecoxibLoxoprofenPlacebo
Incidence of Treatment-emergent, All-causality GI Body System Adverse Events24.347.416.2

Adverse events

Collected over 2 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—0/76 (0%)19/76 (25%)
Loxoprofen—0/76 (0%)37/76 (48.7%)
Placebo—0/37 (0%)8/37 (21.6%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventCelecoxibLoxoprofenPlacebo
Gastritis erosiveGastrointestinal disorders8/7628/763/37
Erosive duodenitisGastrointestinal disorders1/765/760/37
DiarrhoeaGastrointestinal disorders1/762/762/37
Abdominal discomfortGastrointestinal disorders2/764/760/37
Gastric ulcerGastrointestinal disorders0/764/760/37
SomnolenceNervous system disorders1/764/760/37
Abdominal distensionGastrointestinal disorders0/763/760/37
DyspepsiaGastrointestinal disorders1/760/761/37
OesophagitisGastrointestinal disorders0/760/761/37
Bilirubin conjugated increasedInvestigations0/760/761/37

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CelecoxibLoxoprofenPlaceboTotal
Mean56.5 ± 9.6557.8 ± 9.3859.1 ± 9.1857.5 ± 9.45
Sex: Female, Male
Sex: Female, Male(Participants)CelecoxibLoxoprofenPlaceboTotal
Female545526135
Male22211154
Helicobacter pylori (H. pylori) status
Helicobacter pylori (H. pylori) status(Participants)CelecoxibLoxoprofenPlaceboTotal
Positive32331681
Negative444321108
08

Study locations

3 sites
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Minato-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinjuku-ku, Tokyo, Japan
09

References and documents

Publications

  • Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther. 2013 Feb;37(3):346-54. doi: 10.1111/apt.12174. Epub 2012 Dec 10. PubMed 23216412 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2009
First posted
Oct 14, 2009
Start
Nov 2009
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
May 17, 2011
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00994461
Responsible party
Sponsor
First posted
Oct 14, 2009
Start date
Nov 2009
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
May 17, 2011
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion